Ondine Biomedical Says LANTERN Phase 3 Study To Report Top-Line Results In Spring 2026
ReutersMar 10, 2026 7:50 AM
March 10 (Reuters) - Ondine Biomedical Inc OBI.L:
ONDINE BIOMEDICAL - ONDINE PROVIDES UPDATE ON US PHASE 3 PIVOTAL STUDY
ONDINE BIOMEDICAL INC - LANTERN PHASE 3 STUDY TO REPORT TOP-LINE RESULTS IN SPRING 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Micron vs. Samsung vs. SK Hynix: Is MU Stock the Best Memory Stock for 2026?
TradingKey - Relying on strong AI demand, more memory per system, and sluggish supply response, 2026 will be the memory cycle. Micron Technology (MU) is now in an excellent competitive position today with HBM3E and looking to ramp HBM4E into Nvidia’s Vera Rubin platforms in the second half of 2026.TradingKey
3 hours ago
Oil Prices Tumble Nearly $40 After Trump Signals End to War, Though Analysts Maintain Hormuz Strait Is the Real Decider
TradingKey - On Monday, March 9 (ET), Trump stated in an interview that the U.S.-Iran war has essentially ended, causing crude oil prices to plummet. Driven by the news, WTI and Brent crude futures, which had reached intraday highs near $120, dropped to the $80 mark.TradingKey
6 hours ago
Oracle Earnings Preview: Warner Bros is Becoming Central to Oracle's Future
How is the WBD Deal Affecting ORCL Stock?TradingKey
7 hours ago
Jensen Huang’s Bold Message: DRAM Fabs Should Expand, Nvidia Will Buy It All.
TradingKey - Nvidia (NVDA) CEO Jensen Huang recently delivered a powerful signal to global memory chip manufacturers at the Morgan Stanley Technology Conference: expand production with confidence, as Nvidia will take all available supply.TradingKey
23 hours ago
